Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.97 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.97 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.97 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | RHOC | P08134 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.97 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.97 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.84 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.84 |
| ▸ | PDE6D | O43924 | 3/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL618614 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL14968747 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL19469652 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL34266 | 1.00 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL524785 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL7037657 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL1402150 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL28270206 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL5451363 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL28457 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4299063-B1 | ORAL CAPSULES COMPRISING ATORVASTATIN TABLETS SHOWING SUITABLE DISSOLUTION PROFILE AND BIOAVAILABILITY | FERRER INT (ES) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024003281-A1 | ORAL CAPSULES COMPRISING ATORVASTATIN TABLETS SHOWING SUITABLE DISSOLUTION PROFILE AND BIOAVAILABILITY. | FERRER INTERNACIONAL, S.A. (ES) | 2024-01-04 | — | — | WO | disclosed |
| EP-4299063-A1 | ORAL CAPSULES COMPRISING ATORVASTATIN TABLETS SHOWING SUITABLE DISSOLUTION PROFILE AND BIOAVAILABILITY | Ferrer Internacional, S.A. (ES) | 2024-01-03 | — | — | EP | disclosed |
| CN-110913843-B | Pharmaceutical composition | 伊莱利利公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-110913843-A | Pharmaceutical composition | 伊莱利利公司 | 2020-03-24 | — | — | CN | disclosed |